ModernaTX
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, ModernaTX sits in the top decile of US sponsors by registered trial count (#261 of 15,742 sponsors by registered trial count).
ModernaTX: 90 sponsored US clinical trials, 13 recruiting.
ModernaTX sponsors 90 registered US clinical trials on ClinicalTrials.gov, 13 of them currently recruiting, and 58 completed. 19 of these trials are in Phase 3-4 (later-stage) and 58 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Respiratory Syncytial Virus, with 5 trials.
Top-decile sponsor footprint
ModernaTX ranks in the top decile of sponsors by registered trial count (#261 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
58 of 62 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
90 total, page 2 of 2
Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study
NCT05572658
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
NCT05566639
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
NCT05436834
Use of Wearable Digital Sensors After mRNA Vaccination in Adults
NCT05440318
A Study of Modified mRNA Vaccines in Healthy Adults
NCT05397223
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
NCT05375838
A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
NCT05367908
A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
NCT05333289
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
NCT05330975
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters
NCT05137236
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
NCT05127434
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647
NCT05105048
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
NCT05085366
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
NCT05366322
Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
NCT04958304
Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States
NCT04958954
A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
NCT04956575
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
NCT04975893
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
NCT04917861
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
NCT04927065
A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants
NCT04860297
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
NCT04796896
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
NCT04813796
A Study of the Effectiveness of Moderna COVID-19 Vaccine
NCT05933304
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
NCT04649151
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive
NCT04528719
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
NCT04470427
Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older
NCT04405076
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
NCT04232280
Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
NCT04144348
Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
NCT04064905
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults
NCT03829384
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
NCT03739931
"The MaP Study": Mapping the Patient Journey in MMA and PA
NCT03484767
Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults
NCT03392389
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
NCT03382405
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
NCT03323398
Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants
NCT03325075
Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects
NCT03014089
Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects
NCT03345043
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 39 |
| Phase 2 | 19 |
| Phase 3 | 15 |
| Phase 4 | 4 |
What is open in the ModernaTX pipeline
13 recruiting of 90 indexed (14% open); 58 completed (64%).
Phase mix: 19 late (III/IV) vs 58 early (I/II) (early-phase heavy).
Top condition: Respiratory Syncytial Virus (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ModernaTX: open-pipeline peers nationwide
Peers matched on 90 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
ModernaTX sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 90 trials (± recruiting share)
- Hackensack Meridian Health · 90 trials · 26% recruiting
- National Institute of Dental and Craniofacial Research (NIDCR) · 91 trials · 12% recruiting
- University of Central Florida · 91 trials · 42% recruiting
- Abbott Nutrition · 89 trials · 1% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Masonic Cancer Center, University of Minnesota · 14% recruiting · 249 trials
- The Cleveland Clinic · 14% recruiting · 688 trials
- University of Wisconsin, Madison · 15% recruiting · 1,039 trials
- Dana-Farber Cancer Institute · 14% recruiting · 781 trials
Related
What to do with this ModernaTX page
90 registered trials is a research-attention snapshot, not an endorsement of ModernaTX or any single study.
- 13 of ModernaTX's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Respiratory Syncytial Virus is the condition ModernaTX studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Respiratory Syncytial Virus trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ModernaTX pipeline card: 90 registered trials from official public datasets.Report a data error.